Navigation Links
PTC Therapeutics' President and CEO Elected AAAS Fellow
Date:1/19/2011

SOUTH PLAINFIELD, N.J., Jan. 19, 2011 /PRNewswire/ -- Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and publisher of the journal Science.  AAAS Fellows are chosen by their peers and recognized for their scientifically or socially distinguished efforts to advance science or its applications.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

As part of the Biological Science Section, Dr. Peltz is recognized for his "distinguished contributions in the area of genetics and RNA biochemistry, specifically mRNA stability and decay."  Dr. Peltz co-founded PTC Therapeutics in 1998 with the goal of discovering, developing and commercializing innovative therapies in areas of high unmet medical need based on RNA biochemistry and post-transcriptional control mechanisms.  While a total of 503 Fellows were recognized for 2010, Dr. Peltz is one of only ten Fellows elected who are currently in industry.  

"On behalf of the Board and the broader PTC community, we all congratulate Stuart for the AAAS Council's recognition for the excellence and value of his work in genetics and RNA biochemistry.  We all agree this is well deserved," said Michael Schmertzler, Chairman of the Board of Directors of PTC Therapeutics.

The tradition of AAAS Fellows began in 1874.  Currently, members can be considered for the rank of Fellow if nominated by the steering groups of the Association's 24 sections, or by any three Fellows who are current AAAS members, or by the AAAS chief executive officer.  Each steering group then reviews the nominations of individuals within its respective section and forwards a final list to the AAAS Council.  The AAAS Council, the association's policymaking body, votes on the final list.

"This is a great honor, for which a very large portion of the credit goes to my students, collaborators, colleagues and employees at PTC," said Dr. Stuart Peltz, President and CEO.  "We are committed to applying innovative science to develop therapies for diseases that currently have little or no treatment options."  

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes.  Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function.  PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases.  PTC has developed proprietary technologies that it applies in its drug discovery activities and is the basis for collaborations with leading biopharmaceutical companies.  For more information, visit the company's web site at www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
2. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
3. Echo Therapeutics to Present at the OneMedForum 2011 Conference
4. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
5. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
6. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
7. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
9. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
10. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
11. Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Volumes: Global Analysis (United States, China, Japan, Brazil, United ... to their offering. ... healthcare business planners, provides surgical procedure volume data in ... with an in-depth analysis of growth drivers and inhibitors, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):